Epigenetic silencing of miR-26A1 in chronic lymphocytic leukemia and mantle cell lymphoma: Impact on EZH2 expression

References

• Tashkandi H, Shah N, Patel Y, Chen H. Identification of new miRNA biomarkers associated with HER2-positive breast cancers. Oncoscience 2015; 2:924-9; PMID:26697527
   PubMedGoogle Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136:215-33; PMID:19167326; http://dx.doi.org/10.1016/j.cell.2009.01.002
   PubMed Web of Science ®Google Scholar
• Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer research 2005; 65:7065-70; PMID:16103053; http://dx.doi.org/10.1158/0008-5472.CAN-05-1783
   PubMed Web of Science ®Google Scholar
• Omrane I, Kourda N, Stambouli N, Privat M, Medimegh I, Arfaoui A, Uhrhammer N, Bougatef K, Baroudi O, Bouzaienne H, et al. MicroRNAs 146a and 147b biomarkers for colorectal tumor's localization. Biomed Res Int 2014; 2014:584852; PMID:24800242; http://dx.doi.org/10.1155/2014/584852
   PubMed Web of Science ®Google Scholar
• Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002; 99:15524-9; PMID:12434020; http://dx.doi.org/10.1073/pnas.242606799
   PubMed Web of Science ®Google Scholar
• Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, Shimizu M, Cimmino A, Zupo S, Dono M, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A 2004; 101:11755-60; PMID:15284443; http://dx.doi.org/10.1073/pnas.0404432101
   PubMed Web of Science ®Google Scholar
• Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353:1793-801; PMID:16251535; http://dx.doi.org/10.1056/NEJMoa050995
   PubMed Web of Science ®Google Scholar
• Fulci V, Chiaretti S, Goldoni M, Azzalin G, Carucci N, Tavolaro S, Castellano L, Magrelli A, Citarella F, Messina M, et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 2007; 109:4944-51; PMID:17327404; http://dx.doi.org/10.1182/blood-2006-12-062398
   PubMed Web of Science ®Google Scholar
• Zhang J, Jima DD, Jacobs C, Fischer R, Gottwein E, Huang G, Lugar PL, Lagoo AS, Rizzieri DA, Friedman DR, et al. Patterns of microRNA expression characterize stages of human B-cell differentiation. Blood 2009; 113:4586-94; PMID:19202128; http://dx.doi.org/10.1182/blood-2008-09-178186
   PubMed Web of Science ®Google Scholar
• Deng SY, Guo XX, Wang N, Wang KH, Wang S. Network analysis of microRNAs, genes and their regulation in mantle cell lymphoma. Asian Pac J Cancer Prev 2015; 16:457-63; PMID:25684471; http://dx.doi.org/10.7314/APJCP.2015.16.2.457
   PubMedGoogle Scholar
• Husby S, Geisler C, Gronbaek K. MicroRNAs in mantle cell lymphoma. Leuk Lymphoma 2013; 54:1867-75; PMID:23339447; http://dx.doi.org/10.3109/10428194.2013.766731
   PubMed Web of Science ®Google Scholar
• Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A, Volinia S, Coluzzi S, Leone V, Borbone E, et al. Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 2007; 26:7590-5; PMID:17563749; http://dx.doi.org/10.1038/sj.onc.1210564
   PubMed Web of Science ®Google Scholar
• Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, Barth TF, Moller P, Stilgenbauer S, Pollack JR, Wirth T. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 2008; 112:4202-12; PMID:18713946; http://dx.doi.org/10.1182/blood-2008-03-147645
   PubMed Web of Science ®Google Scholar
• Ciarapica R, Russo G, Verginelli F, Raimondi L, Donfrancesco A, Rota R, Giordano A. Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma. Cell Cycle 2009; 8:172-5; PMID:19106613; http://dx.doi.org/10.4161/cc.8.1.7292
   PubMed Web of Science ®Google Scholar
• Luzi E, Marini F, Sala SC, Tognarini I, Galli G, Brandi ML. Osteogenic differentiation of human adipose tissue-derived stem cells is modulated by the miR-26a targeting of the SMAD1 transcription factor. J Bone Miner Res 2008; 23:287-95; PMID:18197755; http://dx.doi.org/10.1359/jbmr.071011
   PubMed Web of Science ®Google Scholar
• Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419:624-9; PMID:12374981; http://dx.doi.org/10.1038/nature01075
   PubMed Web of Science ®Google Scholar
• Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 2003; 100:11606-11; PMID:14500907; http://dx.doi.org/10.1073/pnas.1933744100
   PubMed Web of Science ®Google Scholar
• Heyn H, Esteller M. EZH2: An Epigenetic Gatekeeper Promoting Lymphomagenesis. Cancer Cell 2013; 23:563-5; PMID:23680141; http://dx.doi.org/10.1016/j.ccr.2013.04.028
   PubMed Web of Science ®Google Scholar
• Lu J, He ML, Wang L, Chen Y, Liu X, Dong Q, Chen YC, Peng Y, Yao KT, Kung HF, et al. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res 2011; 71:225-33; PMID:21199804; http://dx.doi.org/10.1158/0008-5472.CAN-10-1850
   PubMed Web of Science ®Google Scholar
• Dang X, Ma A, Yang L, Hu H, Zhu B, Shang D, Chen T, Luo Y. MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells. Cancer Genet 2012; 205:113-23; PMID:22469510; http://dx.doi.org/10.1016/j.cancergen.2012.01.002
   PubMed Web of Science ®Google Scholar
• Zhao JJ, Lin J, Lwin T, Yang H, Guo J, Kong W, Dessureault S, Moscinski LC, Rezania D, Dalton WS, et al. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 2010; 115:2630-9; PMID:20086245; http://dx.doi.org/10.1182/blood-2009-09-243147
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhao X, Fiskus W, Lin J, Lwin T, Rao R, Zhang Y, Chan JC, Fu K, Marquez VE, et al. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. Cancer Cell 2012; 22:506-23; PMID:23079660; http://dx.doi.org/10.1016/j.ccr.2012.09.003
   PubMed Web of Science ®Google Scholar
• Cahill N, Bergh AC, Kanduri M, Goransson-Kultima H, Mansouri L, Isaksson A, Ryan F, Smedby KE, Juliusson G, Sundstrom C, et al. 450K-array analysis of chronic lymphocytic leukemia cells reveals global DNA methylation to be relatively stable over time and similar in resting and proliferative compartments. Leukemia 2013; 27:150-8; PMID:22922567; http://dx.doi.org/10.1038/leu.2012.245
   PubMed Web of Science ®Google Scholar
• Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94:1840-7; PMID:10477712
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94:1848-54; PMID:10477713
   PubMed Web of Science ®Google Scholar
• Yu L, Lu J, Zhang B, Liu X, Wang L, Li SY, Peng XH, Xu X, Tian WD, Li XP. miR-26a inhibits invasion and metastasis of nasopharyngeal cancer by targeting EZH2. Oncol Lett 2013; 5:1223-8; PMID:23599767; http://dx.doi.org/10.3892/ol.2013.1173
   PubMed Web of Science ®Google Scholar
• Wang G, Sun Y, He Y, Ji C, Hu B, Sun Y. miR-26a promoted by interferon-α inhibits hepatocellular carcinoma proliferation and migration by blocking EZH2. Genet Test Mol Biomarkers 2015; 19:30-6; PMID:25494962; http://dx.doi.org/10.1089/gtmb.2014.0245
   PubMed Web of Science ®Google Scholar
• Kanduri M, Cahill N, Goransson H, Enstrom C, Ryan F, Isaksson A, Rosenquist R. Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. Blood 2010; 115:296-305; PMID:19897574; http://dx.doi.org/10.1182/blood-2009-07-232868
   PubMed Web of Science ®Google Scholar
• Kanduri M, Marincevic M, Halldorsdottir AM, Mansouri L, Junevik K, Ntoufa S, Kultima HG, Isaksson A, Juliusson G, Andersson PO, et al. Distinct transcriptional control in major immunogenetic subsets of chronic lymphocytic leukemia exhibiting subset-biased global DNA methylation profiles. Epigenetics 2012; 7:1435-42; PMID:23154584; http://dx.doi.org/10.4161/epi.22901
   PubMed Web of Science ®Google Scholar
• Halldorsdottir AM, Kanduri M, Marincevic M, Mansouri L, Isaksson A, Goransson H, Axelsson T, Agarwal P, Jernberg-Wiklund H, Stamatopoulos K, et al. Mantle cell lymphoma displays a homogenous methylation profile: a comparative analysis with chronic lymphocytic leukemia. Am J Hematol 2012; 87:361-7; PMID:22374828; http://dx.doi.org/10.1002/ajh.23115
   PubMedGoogle Scholar
• Kulis M, Heath S, Bibikova M, Queiros AC, Navarro A, Clot G, Martinez-Trillos A, Castellano G, Brun-Heath I, Pinyol M, et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet 2012; 44:1236-42; PMID:23064414; http://dx.doi.org/10.1038/ng.2443
   PubMed Web of Science ®Google Scholar
• Oakes CC, Seifert M, Assenov Y, Gu L, Przekopowitz M, Ruppert AS, Wang Q, Imbusch CD, Serva A, Koser SD, et al. DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nat Genet 2016; PMID:26780610; http://dx.doi.org/10.1038/ng.3488
   PubMed Web of Science ®Google Scholar
• Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003; 22:5323-35; PMID:14532106; http://dx.doi.org/10.1093/emboj/cdg542
   PubMed Web of Science ®Google Scholar
• Yu J, Rhodes DR, Tomlins SA, Cao X, Chen G, Mehra R, Wang X, Ghosh D, Shah RB, Varambally S, et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 2007; 67:10657-63; PMID:18006806; http://dx.doi.org/10.1158/0008-5472.CAN-07-2498
   PubMed Web of Science ®Google Scholar
• Kanduri M, Sander B, Ntoufa S, Papakonstantinou N, Sutton LA, Stamatopoulos K, Kanduri C, Rosenquist R. A key role for EZH2 in epigenetic silencing of HOX genes in mantle cell lymphoma. Epigenetics 2013; 8:1280-8; PMID:24107828; http://dx.doi.org/10.4161/epi.26546
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111:5446-56; PMID:18216293; http://dx.doi.org/10.1182/blood-2007-06-093906
   PubMed Web of Science ®Google Scholar
• Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011; 117:5019-32; PMID:21300984; http://dx.doi.org/10.1182/blood-2011-01-293050
   PubMed Web of Science ®Google Scholar
• Martinelli S, Kanduri M, Maffei R, Fiorcari S, Bulgarelli J, Marasca R, Rosenquist R. ANGPT2 promoter methylation is strongly associated with gene expression and prognosis in chronic lymphocytic leukemia. Epigenetics 2013; 8:720-9; PMID:23803577; http://dx.doi.org/10.4161/epi.24947
   PubMed Web of Science ®Google Scholar
• Rosen A, Bergh AC, Gogok P, Evaldsson C, Myhrinder AL, Hellqvist E, Rasul A, Bjorkholm M, Jansson M, Mansouri L, et al. Lymphoblastoid cell line with B1 cell characteristics established from a chronic lymphocytic leukemia clone by in vitro EBV infection. Oncoimmunology 2012; 1:18-27; PMID:22720208; http://dx.doi.org/10.4161/onci.1.1.18400
   PubMed Web of Science ®Google Scholar
• Stacchini A, Aragno M, Vallario A, Alfarano A, Circosta P, Gottardi D, Faldella A, Rege-Cambrin G, Thunberg U, Nilsson K, et al. MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leukemia Res 1999; 23:127-36; PMID:10071128; http://dx.doi.org/10.1016/S0145-2126(98)00154-4
   PubMed Web of Science ®Google Scholar
• Estrov Z, Talpaz M, Ku S, Harris D, Van Q, Beran M, Hirsch-Ginsberg C, Huh Y, Yee G, Kurzrock R. Z-138: a new mature B-cell acute lymphoblastic leukemia cell line from a patient with transformed chronic lymphocytic leukemia. Leukemia Res 1998; 22:341-53; PMID:9669839; http://dx.doi.org/10.1016/S0145-2126(97)00191-4
   PubMed Web of Science ®Google Scholar
• Jadayel DM, Lukas J, Nacheva E, Bartkova J, Stranks G, De Schouwer PJ, Lens D, Bartek J, Dyer MJ, Kruger AR, et al. Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin's lymphomas. Functional studies in a cell line (Granta 519). Leukemia 1997; 11:64-72; http://dx.doi.org/10.1038/sj.leu.2400555
   PubMed Web of Science ®Google Scholar